Interestingly, in glioma or melanoma, TMZ-induced upregulation of NLRP1 and IL-1β is linked to the Notch1 signaling pathway and, subsequently, to the acquisition of drug resistance, as revealed by MAPK inhibitors [178–182]. This evidence concerns the gene NLRP1 and central nervous system cancer.